Decera Clinical Education Oncology Podcast

In this episode, Wassim Abida, MD, PhD; Joaquin Mateo, MD, PhD; and Charles J. Ryan, MD, answer questions from an audience of healthcare professionals on topics related to prostate cancer and PARP inhibition including: Germline and somatic mutation testingPARP inhibition in earlier stage diseasePARP inhibitors plus AR-targeted therapy after progression on AR-targeted therapyPARP inhibition in taxane-sensitive patientsPresenters:Wassim Abida, MD, PhDAssistant MemberAssistant Attending PhysicianGenitourinary Oncology ServiceDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkJoaquin Mateo, MD, PhDGroup LeaderProstate Cancer Translational ResearchVall d'Hebron Institute of OncologyAttending PhysicianMedical OncologyVall d'Hebron University HospitalBarcelona, SpainCharles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/3h1T5oR Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Kaplan, MD, MSc, and Thomas Karasic, MD, review approved immunotherapy options for advanced HCC and answer key questions surrounding use of immune checkpoint inhibitors, with topics including:Current systemic therapy standards of care for patients with advanced HCCUse of single-agent immune checkpoint inhibitor therapy in the first-line settingAssessing bleeding riskUsing immunotherapy in patients with active HBV or HCV infectionsPresenters:David Kaplan, MD, MScAssociate ProfessorPerelman School of MedicineUniversity of PennsylvaniaDirector of HepatologyCorporal Michael J. Crescenz VA Medical CenterPhiladelphia, PennsylvaniaThomas Karasic, MD Assistant Professor of MedicineDepartment of Hematology-OncologyUniversity of PennsylvaniaPhiladelphia, Pennsylvania Content based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Scott Miller, MD, FACOG, FACS, and Melissa M. Hardesty, MD, MPH, provide expert perspectives on new data from ASCO 2021 presented for endometrial, ovarian, and cervical cancers regarding:Results from a pilot study of pembrolizumab monotherapy in patients with Lynch-like vs sporadic MLH1-methylated endometrial cancerUpdated analyses from the phase I GARNET trial, including data for patients with dMMR solid tumors (endometrial cancer and nonendometrial cancer cohorts)Final analyses from a study of mirvetuximab soravtansine plus bevacizumab in platinum-agnostic recurrent ovarian cancerResults from the randomized phase III BOOST trial evaluating optimal treatment duration of bevacizumab in combination with carboplatin and paclitaxel in ovarian cancerHighly anticipated results from the phase III OUTBACK trial of CRT ± adjuvant CT in women with locally advanced cervical cancerA post hoc, pooled analysis, from phase I and phase II data of bintrafusp alfa, a first-in-class bifunctional fusion protein comprising a TGF-βRII (TGF-β trap) fused to a human monoclonal antibody targeting PD-L1Results from a prospective multicenter phase II trial evaluating anlotinib plus sutimlimab in recurrent/advanced cervical cancersPresenters:David Scott Miller, MD, FACOG, FACSAmy and Vernon E. Faulconer Distinguished Chair in Medical ScienceDirector and Dallas Foundation Chair in Gynecologic OncologyProfessor of Obstetrics & GynecologyUniversity of Texas Southwestern Medical CenterMedical Director of Gynecologic OncologyChair, Cancer CommitteeParkland Health & Hospital SystemDallas, Texas Melissa M. Hardesty, MD, MPHAffiliate Associate ProfessorOB/GYN/GYN OncologyUniversity of Alaska AnchorageGynecologic Oncologist and Managing PartnerAlaska Women’s Cancer CareAnchorage, AlaskaContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/3dAttwi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, Suzanne Lentzsch, MD, PhD, and Saad Z. Usmani, MD, MBA, FACP, discuss how they select optimal treatment for relapsed/refractory (R/R) multiple myeloma (MM) and answer audience questions from a live webinar. Topics include:Selecting optimal triplet regimen after first relapseSequencing treatment options after multiple relapsesManaging patient expectations when selecting treatmentsEmerging treatment options for R/R MMPresenters: Suzanne Lentzsch, MD, PhDDirector, Multiple Myeloma and Amyloidosis ProgramProfessor of MedicineDivision of Hematology/OncologyColumbia University Medical CenterNew York, New YorkSaad Z. Usmani, MD, MBA, FACPClinical Professor of MedicineDepartment of Hematologic Oncology & Blood DisordersDivision ChiefPlasma Cell Disorders DivisionLevine Cancer Institute/Atrium HealthCharlotte, North CarolinaSupported by educational grants from Amgen; Bristol-Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Oncopeptides.Link to full program, including an downloadable slidesets and an on-demand webcast:https://bit.ly/3gjr62p Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nathan Pennell, MD, PhD; Jamie E. Chaft, MD; and Stephen V. Liu, MD, answer questions asked by an audience of healthcare professionals during a live CCO webinar on biomarker-driven therapies for NSCLC. Topics include:Choosing between immune checkpoint inhibitor monotherapy and combination therapy with an immune checkpoint inhibitor plus chemotherapy for newly diagnosed NSCLCIncorporating newly approved immunotherapies into practiceEvolving guidelines and recommendations for biomarker testing RNA- vs DNA-based next-generation sequencingInterpretation of NGS resultsUse of frontline TKI therapy for patients with CNS metastasesFuture role of KRAS inhibitors in the treatment of advanced NSCLCImproving rates of biomarker testing in lung cancerPresenters:Nathan Pennell, MD, PhDProfessorDirector, Cleveland Clinic Lung Cancer Medical Oncology ProgramDepartment of Hematology and Medical OncologyCleveland Clinic Taussig Cancer InstituteCleveland, OhioJamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkStephen V. Liu, MDAssociate Professor of MedicineDepartment of Medical OncologyLombardi Comprehensive Cancer CenterGeorgetown UniversityWashington, DCSupported by educational grants from Amgen; Lilly; Regeneron Pharmaceuticals, Inc.; and Sanofi Genzyme. For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.Link to full program, including an downloadable slidesets and an on-demand webcast:https://bit.ly/3npjyyb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,Egbert F. Smit, MD, PhD; David Planchard, MD, PhD; and Helena A. Yu, MD, answer audience questions from a live webinar regarding clinical data on antibody–drug conjugates in NSCLC including:Biopsies and biomarker testing considerationsTumor heterogeneity and targeting of brain metastasesLiquid biopsiesSequencing of ADCs following previous therapyToxicity managementPresenters:Egbert F. Smit, MD, PhDProfessorDepartment of Pulmonary DiseasesLeiden University Medical CenterLeiden, NetherlandsDepartment of Thoracic OncologyNetherlands Cancer InstituteAmsterdam, NetherlandsDavid Planchard, MD, PhDHead of Thoracic GroupDepartment of Medical OncologyInstitute Gustave RoussyVillejuif, FranceHelena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC - Oncology - Clinical Care Options (clinicaloptions.com)Link to full program:https://bit.ly/3fr2G6G Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations key considerations for hepatologists, oncologists, and other healthcare professionals in the contemporary use of immune checkpoint inhibitors for treating specific case patients with advanced hepatocellular carcinoma, including:First-line systemic treatment for a patient with Child-Pugh A liver function and no elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh A liver function and elevated bleeding riskFirst-line systemic treatment for a patient with Child-Pugh B liver functionSecond-line systemic treatment for a patient previously receiving atezolizumab plus bevacizumabManagement of immune-mediated hepatitis in a patient with HBV receiving an immune checkpoint inhibitorPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Georgios Gakis, MD, and Mario Wolfgang Kramer, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in Germany. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyPresenters:Georgios Gakis, MD Professor of Urology, Staff UrologistUniversity Hospital of Würzburg Würzburg, GermanyMario Wolfgang Kramer, MD, PhD Consultant UrologistVice Director, UrologyUniversity Hospital Schlewig-Holstein Campus LübeckLübeck, GermanyContent based on an online IME program supported by an educational grant from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand webcast:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, discuss toxicities associated with FGFR inhibitors used in the treatment of urothelial cancer and other malignancies Presenters:Ignacio Durán, MD, PhDAssociate ProfessorGU Oncology Program LeaderDepartment of Medical OncologyHospital Universitario Marques de Valdecilla-IdivalSantander, SpainAlison Birtle, MD, FRCP, FRCRHonorary Senior LecturerFaculty of Health and MedicineUniversity of ManchesterManchester, United KingdomConsultant OncologistRosemere Cancer CentreLancashire Teaching HospitalsPreston, Lancashire, United KingdomContent based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.Link to full program:http://bit.ly/3cf28jH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Joleen Hubbard, MD, and John L. Marshall, MD, discuss use of the later-line treatment options regorafenib and TAS-102 for patients with mCRC, with topics including:Key data supporting the clinical use of these agentsOptimal sequencing and timing of useDosing considerationsKey adverse eventsPresenters:Joleen Hubbard, MDAssociate ProfessorGastrointestinal OncologistMedical OncologyMayo ClinicRochester, MinnesotaJohn L. Marshall, MDChief, Division of Hematology/OncologyDepartment of MedicineGeorgetown University HospitalWashington, DCContent based on an online CME program supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Link to full program: BITLY NEEDED Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Shaji K. Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD, and Jesús F. San-Miguel, MD, PhD, answer audience questions from a recent Clinical Care Options live webinar on managing multiple myeloma. Topics include:Approaches for managing smoldering multiple myelomaInsights on new strategies for managing newly diagnosed multiple myelomaIncorporating newly approved agents in the frontline and early relapse settingChoosing and sequencing BCMA-targeted therapiesManaging patients with refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaThomas G. Martin, MDClinical Professor of MedicineAssociate Director, Myeloma ProgramUniversity of California, San Francisco Medical CenterSan Francisco, CaliforniaPhilippe Moreau, MDProfessor of Clinical HematologyHead, Hematology DepartmentUniversity Hospital Hôtel-DieuNantes, FranceS. Vincent Rajkumar, MDEdward W. and Betty Knight Scripps Professor of MedicineMayo ClinicRochester, MinnesotaJesús F. San-Miguel, MD, PhDDirector of Clinical and Translational MedicineUniversidad de NavarraPamplona, SpainSupported by educational grants from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm and Oncopeptides.Link to full program, including downloadable slidesets and expert commentaries:https://bit.ly/39MWNid Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, consider the potential implications of ongoing and planned clinical trials using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:PARP inhibitors combined with androgen receptorsPhase III trials of PARP inhibitors with androgen receptor–directed therapyPARP inhibitors combined with immunotherapyPARP inhibitors and DNA damaging agentsPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineInstitut Gustave RousseyVillejuif, FranceJoaquin Mateo, MD, PhDAttending PhysicianMedical OncologyVall d’Hebron University Hospital,Barcelona, SpainContent is part of an online program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:https://bit.ly/3spLzqa Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Karim Fizazi, MD, PhD, and Joaquin Mateo, MD, PhD, discuss the underlying rationale for using PARP inhibitors in combination with other therapies to treat men with prostate cancer including:Possible synergy between PARP inhibitors and androgen receptor–directed therapyRationale for PARP inhibitors and immunotherapy combinationsBenefits and challenges of combining DNA damaging agents and PARP inhibitorPresenters:Karim Fizazi, MD, PhDFull ProfessorCancer MedicineInstitut Gustave RousseyVillejuif, FranceJoaquin Mateo, MD, PhDAttending PhysicianMedical OncologyVall d’Hebron University Hospital,Barcelona, SpainContent is part of an online program supported by an educational grant from Pfizer Inc.Link to full program, including associated downloadable Podcast Pearls slidesets, expert analysis, and expert commentary:https://bit.ly/3spLzqa Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jubilee Brown, MD, and Ursula Matulonis, MD, provide expert perspectives on new data from SGO 2021 presented for endometrial and ovarian cancer including:Results from KEYNOTE-775, a phase III trial of lenvatinib plus pembrolizumab in advanced endometrial cancerResults from the confirmatory phase III ARIEL4 evaluating rucaparib vs chemotherapy in BRCA-mutated relapsed ovarian cancer5-year follow-up from SOLO-1 trial of olaparib vs placebo in BRCA-mutated, newly diagnosed ovarian cancerLong-term follow-up results from the phase III ENGOT-OV16/NOVA trial of niraparib in patients with recurrent ovarian cancerOPAL: a phase II study evaluating dostarlimab, bevacizumab, and niraparib in platinum-resistant ovarian cancerPresenters:Jubilee Brown, MDProfessor and Director of Gynecologic OncologyLevine Cancer InstituteAtrium HealthCharlotte, North CarolinaUrsula Matulonis, MDChief, Division of Gynecologic OncologyBrock Wilson Family ChairDana-Farber Cancer InstituteProfessor of MedicineHarvard Medical SchoolBoston, MassachusettsContent supported by an educational grant from GlaxoSmithKline.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:https://bit.ly/3dAttwi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Charles J. Ryan, MD, and Neal D. Shore, MD, FACS, answer questions from a healthcare professional audience on topics related to prostate cancer and PARP inhibition including:Germline and somatic mutation testingManaging adverse events with PARP inhibitorsResistance to PARP inhibitorsImplications of monoallelic vs biallelic BRCA mutationsATM mutations and PARP inhibitor sensitivityPresenters:Charles J. Ryan, MDProfessor of MedicineB.J. Kennedy Chair in Clinical Medical OncologyDirector, Division of Hematology, Oncology and TransplantationDepartment of MedicineUniversity of MinnesotaOncologistDivision of Hematology, Oncology and TransplantationUniversity of Minnesota Health Clinics and Surgery CenterMinneapolis, MinnesotaNeal D. Shore, MD, FACSDirectorCarolina Urologic Research CenterAtlantic Urology ClinicsMyrtle Beach, South CarolinaLink to full program, including downloadable slidesets, expert commentaries, and on-demand webcast:https://bit.ly/2P31ZqF Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeremy S. Abramson, MD, MMSc, discusses highlights of the key data from ASH 2020 on the treatment of patients with lymphomas/CLL, with topics including:Approved and Investigational Targeted Therapeutics for CLL Investigational CAR T-Cell Therapy for Indolent Lymphomas, CLL, and Mantle Cell LymphomaBispecific Antibodies and Other Investigational Targeted Agents for LymphomasTreatment for Older Patients With Hodgkin LymphomaPresenters:Jeremy S. Abramson, MD, MMScAssociate Professor Department of Medicine Harvard Medical School Director, Center for Lymphoma Massachusetts General Hospital Boston, MassachusettsContent based on an online CME program supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology.Link to full program:https://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Enriqueta Felip, MD, PhD, and Matthew Gubens, MD, MS, discuss evolving practice standards for EGFR-mutated non-small-cell lung cancer with topics including:Biomarker testing and strategiesOptimal first-line therapy in patients with NSCLCManagement of patients with CNS diseaseSelecting therapy for patients with noncanonical mutationsManagement strategies after progression on first-line EGFR TKI therapySelecting therapy for patients with early stage diseasePresenters: Enriqueta Felip, MD, PhDHead, Thoracic Oncology UnitOncology ServiceVall d'Hebron University HospitalBarcelona, SpainMatthew Gubens, MD, MSAssociate ProfessorThoracic OncologyUniversity of California, San FranciscoSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/2PpFFHM Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Ignacio Durán, MD, PhD, and Alison Birtle, MD, FRCP, FRCR, interpret the latest clinical data on targeting FGFR in urothelial cancer Presenters:Ignacio Durán, MD, PhDAssociate ProfessorGU Oncology Program LeaderDepartment of Medical OncologyHospital Universitario Marques de Valdecilla-IdivalSantander, SpainAlison Birtle, MD, FRCP, FRCRHonorary Senior LecturerFaculty of Health and MedicineUniversity of ManchesterManchester, United KingdomConsultant OncologistRosemere Cancer CentreLancashire Teaching HospitalsPreston, Lancashire, United KingdomContent based on an online IME program supported by educational grants from Janssen Pharmaceutica NV.Link to full program:http://bit.ly/3cf28jH Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michael J. Pishvaian, MD, PhD, and Rachna Shroff, MD, answer audience questions from a live CCO webinar focused on current best practices and emerging strategies in pancreatic cancer treatment, with questions including:What is your preferred regimen for neoadjuvant therapy in patients with resectable disease?How do you sequence therapy for patients with metastatic pancreatic cancer?How can you manage a patient who develops significant diarrhea with FOLFIRINOX?Are cisplatin and oxaliplatin equally efficacious for patients with BRCA-mutant disease?How should maintenance olaparib be used?Presenters:Michael J. Pishvaian, MD, PhD Associate Professor of OncologyDirector, Gastrointestinal, Developmental Therapeutics, and Clinical Research ProgramsNCR Kimmel Cancer Center at Sibley Memorial HospitalJohn Hopkins University School of MedicineWashington, DCRachna Shroff, MDAssociate Professor of MedicineChief, Section of GI Medical OncologyDirector, UACC Clinical Trials OfficeThe University of Arizona Cancer CenterTucson, Arizona Content based on an online CME program supported by educational grants from Bristol-Myers Squibb and Ipsen Group.Link to full program:http://bit.ly/314BALT Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Frederick L. Locke, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with lymphomas, with questions including:How does the recent approval of lisocabtagene maraleucel and the expanded indication for axicabtagene ciloleucel add to the treatment landscape for DLBCL? Do you see CAR T-cell therapy ever being used in the first-line setting for DLBCL?How should physicians select patients for CAR T-cell therapy vs ASCT in DLBCL?How should physicians sequence CAR T-cell therapy vs BTK inhibitors in MCL?Presenter:Frederick L. Locke, MDCo-LeaderMoffitt Immuno-Oncology ProgramVice Chair and Associate Member Department of Blood and Marrow Transplant and Cellular ImmunotherapyResearch Director and Medical DirectorImmune Cell Therapy ProgramMoffitt Cancer CenterTampa, FloridaContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program: https://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, D. Ross Camidge, MD, PhD, and Joel W. Neal, MD, PhD, answer questions on investigational antibody-drug conjugates for advanced NSCLC Presenters:Ross Camidge, MD, PhD Professor of Medicine/Oncology University of Colorado Cancer CenterAurora, ColoradoJoel W. Neal, MD, PhD Associate Professor of MedicineDivision of OncologyDepartment of MedicineStanford UniversityAttending PhysicianStanford Cancer InstitutePalo Alto, CaliforniaContent based on an online IME program supported by educational grants from Daiichi Sankyo, Inc .Link to full program:http://bit.ly/3twpIyl Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Noopur Raje, MD, answers audience questions from a live CCO Webinar focused on emerging strategies in the use of CAR T-cell therapy for patients with multiple myeloma and key toxicities associated with CAR T-cell therapy, with questions including:Now that belantamab mafodotin is approved for relapsed/refractory multiple myeloma, what are your thoughts on how BCMA-directed CAR T-cell therapy might be sequenced? Is there reason to think CAR T-cell therapy would still be efficacious following belantamab mafodotin?Could BCMA-directed CAR T-cell therapy replace transplant in the first-line setting for multiple myeloma?What are key considerations surrounding the use of tocilizumab for managing cytokine-release syndrome?What are some of the longer-term toxicities associated with CAR T-cell therapy? When do they emerge and how long do they typically last?Presenter:Noopur Raje, MDProfessor of MedicineHarvard Medical SchoolDirectorCenter for Multiple MyelomaMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by educational grants from Bristol-Myers Squibb and Kite Pharma.Link to full program:http://bit.ly/3rDeFCV Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Dr. Shaji Kumar from the Mayo Clinic and Dr. Sagar Lonial from Emory University discuss highlights of the key data from ASH 2020 on the treatment of patients with multiple myeloma. Topics include:Newly diagnosed multiple myelomaRelapsed/refractory multiple myelomaAnti-BCMA therapy: CAR T-cellsAnti-BCMA therapy: bispecific antibodiesAnti-BCMA therapy: antibody–drug conjugatesNovel targeted agents for relapsed/refractory multiple myelomaPresenters:Shaji K. Kumar, MDMark and Judy Mullins Professor of Hematological MalignanciesChair, Myeloma Amyloidosis Dysproteinemia GroupConsultant, Division of HematologyMayo ClinicRochester, MinnesotaSagar Lonial, MDProfessor and ChairDepartment of Hematology and Medical OncologyChief Medical OfficerWinship Cancer Institute of Emory UniversityAtlanta, GeorgiaLink to the CCO website: http://bit.ly/30EqUn0 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jorge Cortes, MD, and Eunice S. Wang, MD, discuss the clinical implications of 3 key studies in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) presented at the virtual ASH 2020 annual conference. Topics include: The macrophage immune checkpoint inhibitor magrolimab in AMLThe STAMP inhibitor asciminib in CML (the ASCEMBL trial)Optimal dosing for the TKI ponatinib in CMLPresenters:Jorge Cortes, MDDirector, Georgia Cancer CenterEminent Scholar, Georgia Research AcademyAugusta, GeorgiaEunice S. Wang, MDProfessor, OncologyChief, Leukemia ServiceDepartment of MedicineRoswell Park Comprehensive Cancer CenterBuffalo, New YorkContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:https://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jamie E. Chaft, MD, provides her expert perspective on new data from WCLC 2020 in early-stage NSCLC, with topics including:Updated results from ADAURA on HRQoL and DFS outcomes with or without postoperative chemotherapy after adjuvant osimertinibAn analysis of the ongoing ITACA study of personalizing chemotherapy based on biomarkers of drug resistanceFDG PET/CT adaptive radiotherapy in RTOG 1106The TALENT study in Taiwan screening nonsmokers for lung cancerPresenter:Jamie E. Chaft, MDAssociate Attending PhysicianThoracic Oncology ServiceMemorial Sloan Kettering Cancer CenterNew York, New YorkContent supported by educational grants from Amgen; Bristol-Myers Squibb; Ipsen Biopharmaceuticals; Janssen Pharmaceutica NV; Jazz Pharmaceuticals; Regeneron Pharmaceuticals, Inc. & Sanofi Genzyme; and Takeda Oncology.Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:http://bit.ly/2NzE6X6 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, José Ignacio Nolazco, MD, and Alejandro Nolazco, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer from an Argentinian perspective. Presenters:José Ignacio Nolazco, MD Urology FellowHospital Universitario AustralBuenos Aires, ArgentinaAlejandro Nolazco, MDAssociate ProfessorDepartment of UrologyUniversidad Austral and Universidad Católica ArgentinaBuenos Aires, ArgentinaContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program, including associated downloadable slidesets and on-demand Webcast:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Hanny Al-Samkari, MD; Sujit Sheth, MD; and Mark A. Schroeder, MD, provide their clinical perspectives on new data from ASH 2020 on nonmalignant hematologic disorders, with topics including:Use of mycophenolate mofetil plus corticosteroids vs standard corticosteroid treatment in patients with ITP from the phase III FLIGHT study Analysis of an ongoing phase I/II trial of rilzabrutinib reporting safety and efficacy in the long-term extension for adult patients with relapsed/refractory ITPNew data from the phase III HOPE-B study of etranacogene dezaparvovec gene therapy, using an AAV5-vector to deliver the Padua variant of the factor IX gene in patients with hemophilia B An update from the phase I/II CLIMB THAL-111/SCD-121 studies reporting safety and efficacy on the first 10 patients receiving CTX001 with at least 3 months of follow-upPrimary analysis from the phase III REACH3 trial evaluating ruxolitinib, an oral JAK1/2 inhibitor, in combination with steroids and calcineurin inhibitors, as a treatment for steroid-refractory or steroid-dependent chronic GVHDTop-line results from the phase II ROCKstar study of belumosudil, a ROCK2 kinase inhibitor, in patients with heavily pretreated chronic GVHDPhase I data from the GRAVITAS-119 study of JAK1 inhibitor itacitinib plus calcineurin inhibitors as prophylaxis treatment for acute GVHDPresenters:Hanny Al-Samkari, MDInstructorDepartment of MedicineHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsSujit Sheth, MDProfessorDepartment of PediatricsWeill Cornell MedicineNew York, New YorkMark A. Schroeder, MDAssociate Professor of MedicineDivision of OncologyDepartment of MedicineWashington University School of Medicine in St LouisSt Louis, MissouriContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc.; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc.; Novartis; PharmaEssentia Corp.; Seattle Genetics; and Takeda Oncology. Link to full program, including downloadable slidesets, and on-demand Webcasts:http://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Amy E. DeZern, MD, MHS, and Srdan Verstovsek, MD, provide medical oncology and hematology perspectives on new data from ASH 2020 in MDS and MPNs, with topics including:3-year OS results with RIC allogeneic transplantation in patients with higher-risk MDS in the BMT CTN 1102 studyA post hoc analysis of phase II data on the addition of pevonedistat to azacitidine in higher-risk MDS patients5-year results of ropeginterferon α-2b in polycythemia vera from the CONTINUATION-PV studyPhase II results of luspatercept for anemia in patients with myelofibrosis who are transfusion dependentAnalysis of clinical benefit in patients with myelofibrosis and OS benefit from imetelstat.Presenters:Amy E. DeZern, MD, MHSAssociate ProfessorOncology and MedicineThe Johns Hopkins University School of MedicineBaltimore, MarylandSrdan Verstovsek, MD, PhDProfessorDivision of Cancer MedicineDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasContent supported by educational grants from Amgen; AstraZeneca; Bristol-Myers Squibb; Epizyme, Inc; GlaxoSmithKline; Incyte Corporation; Janssen Biotech; Karyopharm Therapeutics Inc; Novartis; PharmaEssentia Corp; Seattle Genetics; and Takeda Oncology.Link to full program and Capsule Summary downloadable slidesets:http://bit.ly/3tyQ9nG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Guiseppe Procopio, MD, and Cora N. Sternberg, MD, FACP, discuss in Italian the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Guiseppe Procopio, MD Head of the Medical Oncology Genitourinary, Istituto Nazionale TumoriMedical OncologyFondazione IRCCS Istituto Nazionale dei TumoriMilan, ItalyCora N. Sternberg, MD, FACPProfessor of MedicineDepartment of Hematology/OncologyWeill Cornell MedicineNew York, New York, USAContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program, including associated downloadable slidesets and on-demand Webcast: http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Michael Callaghan, MD; Miguel A. Escobar, MD; and Rebecca Kruse-Jarres, MD, MPH, answer questions from a clinician audience on topics related to hemophilia management including:Maintaining long-term musculoskeletal healthIdentifying patients most likely to benefit from pharmacokinetics-guided prophylaxisManaging combination therapies in older patients with comorbiditiesYoungest age at which patients can be considered for emicizumabDevelopment of resistance to emicizumabSwitching recombinant factor therapiesUsing bypassing agents with emicizumab for breakthrough bleeds in patients with inhibitorsPotential clinical role of extending FVIII half-life with BIVV001Considerations when dosing emicizumab monthlyPresenters:Michael Callaghan, MDAssociate ProfessorDepartment of HematologyWayne State UniversityHematologistDivision of Hematology/OncologyChildren’s Hospital of MichiganDetroit, MichiganMiguel A. Escobar, MDProfessor of Medicine and PediatricsDepartment of HematologyUniversity of Texas Health Science CenterMcGovern Medical SchoolDirectorGulf States Hemophilia and Thrombophilia CenterHouston, TexasRebecca Kruse-Jarres, MD, MPHProfessorDepartment of MedicineUniversity of WashingtonExecutive/Medical DirectorWashington Institute for CoagulationSeattle, WashingtonContent supported by educational grants from Genentech, a member of the Roche Group; Sanofi Genzyme Corporation; and Takeda Pharmaceutical Company Ltd.Link to full program, including downloadable slidesets, expert commentaries, and on-demand Webcast: http://bit.ly/2MW5uhi Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Petros Grivas, MD, PhD, and Jonathan E. Rosenberg, MD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United States. Topics include:Guideline changes for first-line UC based on data from JAVELIN Bladder 100 trial on avelumab maintenance after chemotherapyResults from IMvigor130 and KEYNOTE-361 trials on concurrent immune checkpoint inhibition plus chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor monotherapyUtility of PD-L1 as biomarker for immune checkpoint inhibitor–based therapyMonitoring for and managing immune-related adverse events during the COVID-19 pandemic Presenters:Petros Grivas, MD, PhDAssociate ProfessorClinical Director, Genitourinary Cancers ProgramDivision of Medical OncologyDepartment of MedicineUniversity of WashingtonSeattle Cancer Care AllianceSeattle, Washington, USAJonathan E. Rosenberg MDAttending PhysicianChief, Genitourinary Oncology ServiceDivision of Solid Tumor OncologyDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New York, USAContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, discuss key considerations in the contemporary use of immune checkpoint inhibitors for treating patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of nivolumab ± ipilimumab and pembrolizumabEmerging immunotherapy combinations currently being investigated in clinical trialsManagement of key adverse events with immune checkpoint inhibitorsPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:http://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Félix Guerrero Ramos, MD, PhD, FEBU, and Óscar Rodríguez-Faba, MD, discuss in Spanish the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Félix Guerrero Ramos, MD, PhD, FEBU Teaching CollaboratorDepartment of SurgeryMedicine SchoolUniversidad Complutense de MadridAttending UrologistDepartment of UrologyUroOncology UnitMadrid, Spain Óscar Rodríguez-Faba, MD UrologistUro-OncologyFundació PuigvertBarcelona, Catalonia, SpainContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program, including associated downloadable slidesets and on-demand Webcast:http://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Nathan Pennell, MD, PhD, and Laura J. Tafe, MD, provide medical oncology and pathology perspectives, respectively, when answering questions from a clinician audience on topics including:Next steps in patient care after identifying a biomarker: selecting treatment, getting insurance approval, arranging for financial assistancePerforming biomarker testing on cytology vs surgical or anatomic pathology specimensFactors affecting turnaround time when testing liquid biopsy vs tissue specimensChoice of a targeted agent vs chemotherapy plus immunotherapy for first-line treatment of patients with RET fusions, BRAF mutations, or MET exon 14 skippingConcordance between IHC and FISH or NGS for ALK rearrangementsUse of fluid cytology specimens when testing for fusions in RET or NTRK and MET amplificationCost considerations with performing multiple single-gene assays vs upfront NGSTesting for driver mutations in early-stage NSCLCDeveloping institutional workflows to enable pathologists to order reflex molecular testing panelsPresenters:Nathan Pennell, MD, PhDProfessorDirector, Cleveland Clinic Lung Cancer Medical Oncology ProgramDepartment of Hematology and Medical OncologyCleveland Clinic Taussig Cancer InstituteCleveland, OhioLaura J. Tafe, MDAssociate Professor of Pathology and Laboratory MedicineDartmouth-Hitchcock Medical CenterLebanon, New HampshireThe Geisel School of Medicine at DartmouthHanover, New HampshireContent supported by an educational grant from Lilly.Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:http://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode,William G. Wierda, MD, PhD, Jeremy S. Abramson, MD, MMSc, and Brian Hill, MD, PhD, answer questions focused on personalizing therapy for patients with CLL considering patient characteristics and currently available clinical evidence.Presenters:William G. Wierda, MD, PhD, Program DirectorProfessor of MedicineChief, Section of CLLDepartment of LeukemiaThe University of Texas MD Anderson Cancer CenterHouston, TexasJeremy S. Abramson, MD, MMScAssociate ProfessorDepartment of MedicineHarvard Medical SchoolDirector, Center for LymphomaMassachusetts General HospitalBoston, MassachusettsBrian Hill, MD, PhDDirector, Lymphoid Malignancies ProgramTaussig Cancer InstituteCleveland ClinicCleveland, OhioContent based on an online CME program supported by educational grants from AstraZeneca; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Lilly.Link to full program, including associated downloadable slidesets:http://bit.ly/3mLjeIb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Helena A. Yu, MD, and Maria E. Arcila, MD, provide medical oncology and pathology perspectives, respectively, on new data from ESMO 2020 informing precision medicine in NSCLC, with topics including:Updated efficacy data from the phase III ADAURA study of adjuvant osimertinib for resected EGFR-mutated NSCLC with a focus on CNS disease recurrenceBiomarker testing in early-stage lung cancer New data for sotorasib, a small molecule inhibitor of KRAS G12C, in heavily pretreated NSCLCInterim results from the phase I portion of the CHRYSALIS trial evaluating amivantamab, a bispecific antibody that targets EGFR and MET, in combination with lazertinib, a third-generation EGFR TKI, for the treatment of EGFR-mutated NSCLCPhase I data on the HER3-directed antibody–drug conjugate patritumab deruxtecan for NSCLC with progression on an EGFR TKIPresenters:Helena A. Yu, MDAssistant AttendingDepartment of MedicineMemorial Sloan Kettering Cancer CenterNew York, New YorkMaria E. Arcila, MDPathologistDirector, Diagnostic Molecular Pathology LaboratoryMemorial Sloan Kettering Cancer CenterNew York, New YorkContent supported by an educational grant from Lilly.Link to full program, including an associated Podcast Pearls PDF, downloadable slidesets, and on-demand Webcasts:http://bit.ly/3a3e1Xs Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Link to CME: Claim CreditIn this episode, Amit G. Singal, MD, MS, and Lipika Goyal, MD, answer clinician questions on current best practices and emerging applications with immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma, with topics including:Optimal use of the newly approved immune checkpoint inhibitor/VEGF inhibitor combination of atezolizumab plus bevacizumabUse of immune checkpoint inhibitor therapy in patients with Child-Pugh B liver functionUse of biomarkers to inform treatment for patients with advanced HCCPresenters:Amit G. Singal, MD, MSChief of HepatologyMedical Director, Liver Tumor ProgramProfessor, Department of Internal MedicineUT Southwestern Medical CenterDallas, TexasLipika Goyal, MDLead of the Liver Cancer Research ProgramAssistant Professor of MedicineHarvard Medical SchoolMassachusetts General Hospital Cancer CenterBoston, MassachusettsContent based on an online CME program supported by an educational grant from Genentech, a member of the Roche Group.Link to full program:https://bit.ly/39V6s72 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Thomas Powles, MBBS, MRCP, MD, and Michiel van der Heijden, MD, PhD, discuss key data on immune checkpoint inhibitors for urothelial carcinoma informing their clinical practice in the United Kingdom and the Netherlands. Topics include:Data from registrational trials in the European Union for pembrolizumab and atezolizumab in the first-line/second-line settingsUtility of PD-L1 and tumor mutational burden as biomarkers for immune checkpoint inhibitor–based therapyResults from the JAVELIN trial on avelumab maintenance after chemotherapyWhen to consider first-line treatment with immune checkpoint inhibitor–based therapy vs chemotherapyPresenters:Thomas Powles, MBBS, MRCP, MDDeputy Centre LeadCentre for Experimental Cancer MedicineBarts Cancer InstituteQueen Mary University of LondonProfessor of Urology CancerDirector of Barts Cancer CentreDepartment of CancerSt Bartholomew's Hospital (Barts Health NHS Trust)London, United KingdomMichiel van der Heijden, MD, PhDMedical Oncologist and Research Group LeaderDepartment of Medical Oncology and Molecular CarcinogenesisStichting Het Nederlands Kanker Instituut – Antoni van Leeuwenhoek ZiekenhuisMedical Oncologist Antoni van Leeuwenhoek Ziekenhuis/Netherlands Cancer InstituteAmsterdam, the NetherlandsContent based on an online IME program supported by educational grants from Pfizer and EMD Serono, Inc.Link to full program, including associated downloadable slidesets and on-demand Webcast:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Alain Ravaud, MD, PhD, and Marine Gross-Goupil, MD, PhD, discuss in French the latest immuno-oncology developments in the treatment of urothelial cancer. Presenters:Alain Ravaud, MD, PhD Professor of Medical OncologyHead of Department of Medical OncologyBordeaux University HospitalBordeaux, FranceMarine Gross-Goupil, MD, PhD Medical OncologistSaint-André HospitalBordeaux University HospitalBordeaux, FranceContent based on an online IME program supported by educational grants from EMD Serono, Inc and Pfizer.Link to full program:https://bit.ly/3kJC5SL Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of molecular testing and classification to guide the use of immunotherapy for the treatment of patients with endometrial cancer. Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University HospitalCopenhagen, DenmarkContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/3kpJeaG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Mansoor Raza Mirza, MD, and Ana Oaknin, MD, PhD, discuss the implications of recent advances in the use of immunotherapy for the treatment of patients with endometrial cancer.Presenters:Ana Oaknin, MD, PhDHead of Gynecologic Tumors UnitMedical Oncology DepartmentVall d´Hebron University HospitalBarcelona, Spain Mansoor Raza Mirza, MDChief OncologistDepartment of Oncology,Rigshopitalet – Copenhagen University HospitalCopenhagen, Denmark Content based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/3kpJeaG Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, David Marks, MD, PhD, and Stéphane de Botton, MD, answer questions from clinicians on management pearls for patients with acute leukemias. Topics include:MRD in the management of ALLTherapy choice for older patients with AMLOptimal use of inotuzumab ozogamicin and blinatumomab for ALLUse of CAR T-cell therapy for acute leukemiasContent based on an online CME program supported by an educational grant from Pfizer Inc.Link to full program:https://bit.ly/3jiCBaD Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Isabelle Ray Coquard, MD, PhD and Bradley J. Monk, MD, FACS, FACOG, discuss current first-line maintenance therapy options for patients with advanced ovarian cancer. Presenters:Prof Isabelle Ray CoquardProfessor of Department of Medical OncologyClinical Science Institute of the Léon Bérard CenterLyon, FranceBradley J. Monk MD, FACS, FACOGProfessorDivision of Gynecologic OncologyArizona Oncology (US Oncology Network)University of Arizona College of Medicine--PhoenixCreighton University School of Medicine at St Joseph's HospitalPhoenix, ArizonaContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/2Scnp2N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listen to Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing for your patients with advanced ovarian cancer.In this episode, Prof Nicoletta Colombo and Bradley J. Monk, MD, FACS, FACOG, discuss current best practices for biomarker testing in the management of patients with advanced ovarian cancer. Topics include:Subtypes of ovarian cancerBRCA mutation testing Homologous recombination deficiency testing Presenters:Professor Nicoletta ColomboProfessor of Obstetrics and GynecologyUniversity of Milan-BicoccaEuropean Institute of OncologyMilan, ItalyBradley J. Monk MD, FACS, FACOGProfessorDivision of Gynecologic OncologyArizona Oncology (US Oncology Network)University of Arizona College of Medicine--PhoenixCreighton University School of Medicine at St Joseph's HospitalPhoenix, ArizonaContent based on an online CME program supported by an educational grant from GlaxoSmithKline.Link to full program:https://bit.ly/2Scnp2N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:Local therapy in the context of MBCChoice of therapy after progression on available standards of careChoice of trastuzumab deruxtecan and tucatinib based on patient presentationManaging patients with CNS metastasesManaging interstitial lung diseasePresenters:Thomas Bachelot, MD, PhDChair, Unicancer Breast Group - UCBGBreast Cancer UnitMedical Oncology Centre Léon BérardLyon, FranceAdam M. Brufsky, MD, PhDProfessor of Medicine Hematology/Oncology University of Pittsburgh School of MedicineAssociate Chief, Hematology-OncologyUniversity of Pittsburgh Cancer InstitutePittsburgh, PennsylvaniaCristina Saura, MD, PhDMedicine and Surgery/Medical OncologyUniversidad Universitat Autònoma Barcelona and Vall d’Hebron Institute of Oncology (VHIO)Head, Breast Cancer ProgramMedical OncologyVall d’Hebron University HospitalBarcelona, SpainContent based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc. Link to full program, including associated downloadable slidesets:https://bit.ly/32A1HMb Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, an expert medical oncology panel led by Elizabeth R. Plimack, MD, MS, with Brian A. Costello, MD, and Martin H. Voss, MD, discusses clinical pearls for the management of patients with metastatic renal cell carcinoma (RCC). Topics include:Treating beyond progression with immunotherapyManagement of patients with less common histologic subtypes of RCCPotential biomarkers for RCCAdverse event managementPresenters:Elizabeth R. Plimack, MD, MSChief, Division of Genitourinary Medical Oncology Director, Genitourinary Clinical Research Professor, Department of Hematology/Oncology Fox Chase Cancer Center Temple Health Philadelphia, PennsylvaniaBrian A. Costello, MDAssociate Professor of Oncology and UrologyDivision of Medical OncologyMayo ClinicRochester, MinnesotaMartin H. Voss, MDClinical Director, Genitourinary Medical Oncology ServiceMemorial Sloan Kettering Cancer CenterAssistant Professor Weill Cornell Medical CollegeNew York, New YorkContent based on an online CME program supported by educational grants from Eisai, Exelixis, and Pfizer and EMD Serono.Link to full program:https://bit.ly/32IS9gx Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer questions focused on the optimizing BTK inhibitor therapy for previously untreated patients with CLL considering presentation characteristics and drug pharmacology.Presenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:• The impact of COVID-19 on CLL treatment decisions• The use of anti-CD20 antibodies in combination with BTK inhibitors• Considerations when recommending BTK inhibitors• MRD testing in patients with CLL• The potential impact of targeted therapies on when to start treatmentPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets: https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this podcast episode, listen to lung cancer experts Joshua Bauml, MD, a medical oncologist, and Dara L. Aisner, MD, PhD, a molecular pathologist, discuss clinical considerations for patients with RET fusion–positive NSCLC, with topics including:Optimal testing for RET fusionsDNA NGS vs RNA NGSMolecular testing workflowsUsing new selective RET inhibitors to treat patients with RET fusion–positive NSCLCCommon toxicities with new selective RET inhibitorsInterdisciplinary communication between medical oncologists and pathologistsPresenters:Dara L. Aisner, MD, PhDAssociate ProfessorDepartment of PathologyDirector, Molecular PathologyUniversity of ColoradoAurora, ColoradoJoshua Bauml, MDAssistant Professor of MedicineDivision of Hematology/OncologyPerelman School of Medicine at the University of PennsylvaniaPhiladelphia, PennsylvaniaLink to full program, including associated downloadable slidesets:https://bit.ly/2Fsq9Wv Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode, Jeff P. Sharman, MD, Danielle M. Brander, MD, and Nicole Lamanna, MD, answer audience questions from a live Webinar focused on optimal use of BTK inhibitor therapy in patients with CLL, with topics including:Rechallenging patients with venetoclax and BTK inhibitors Mechanism by which BTK inhibitors may reduce infusion reactionsRisk of secondary malignancies with BTK inhibitionDifferent cytogenetic findings and adverse event riskPresenters:Jeff P. Sharman, MD, Program DirectorMedical DirectorHematology ResearchUS Oncology ResearchEugene, OregonDanielle M. Brander, MDAssistant Professor of MedicineDivision of Hematologic Malignancies & Cellular TherapyDepartment of MedicineDuke UniversityAttending Physician, Hematologic MalignanciesDuke University Health SystemDurham, North CarolinaNicole Lamanna, MDAssociate AttendingLeukemia ServiceDirector of CLL ProgramHematologic Malignancies SectionDepartment of MedicineNew York-Presbyterian/Columbia University Medical Center New York, New YorkContent based on an online CME program supported by an educational grant from AstraZeneca.Link to full program, including associated downloadable slidesets:https://bit.ly/3hATX0L Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.